Prof. Long's data were from an independent, investigator-driven ABC (Anti-PD-1 Brain Collaboration) trial, which compared the combination of ipilimumab and nivolumab with nivolumab alone in melanoma patients with brain metastases. The ABC trialists from Australia and New Zealand enrolled 60 patients who received no treatment for asymptomatic brain metastases to receive the combination of ipilimumab and nivolumab (n=35) or nivolumab alone (n=25).
Rates of complete (CR) and partial (PR) responses were also higher for patients receiving the combination. CR and PR were 26% and 26%, respectively, for patients who received the combination compared with 16% and 4%, respectively for patients who received nivolumab.
Best extracranial responses were also higher for patients receiving the combination (57% vs 29% for nivolumab alone). Three-year intracranial PFS was 43% for patients on the combination and 15% for patients on nivolumab alone. Three-year OS was 49% for patients receiving the combination and 42% for patients receiving nivolumab alone.
Prof. Long reported that there were no unexpected toxicities and that the quality of life was maintained across the study groups.
- Long GV et al. ESMO Congress 2019. Abstract 1311O.
Posted on
Previous Article
« Liquid biopsy to decide the best treatment for NSCLC Next Article
Advanced colorectal cancer and BRAF mutations: triplet combination improves survival »
« Liquid biopsy to decide the best treatment for NSCLC Next Article
Advanced colorectal cancer and BRAF mutations: triplet combination improves survival »
Table of Contents: ESMO 2019
Featured articles
Interview with ESMO President Prof. Josep Tabernero
Breast Cancer
Triple negative breast cancer gets positive news: KEYNOTE-522 interim results
CDK4/6 inhibitors change landscape of breast cancer treatment: 2 studies
Veliparib-chemo combo prolongs survival without disease progression in some advanced breast cancer patients
Lung Cancer
Improved response rates without survival benefit with pembrolizumab in pretreated mesothelioma
Frontline ipilimumab/nivolumab improves OS in advanced NCLSC
First-line osimertinib significantly lengthens OS in NSCLC
Liquid biopsy to decide the best treatment for NSCLC
Melanoma
Long-term data from CheckMate 067
Adjuvant nivolumab provides benefit
Nivolumab+ipilimumab superior to monotherapy for melanoma brain metastases
GI Cancers
Preoperative chemotherapy for colon cancer
Nivolumab improves OS in advanced oesophageal cancer
Liquid biopsy identifies relapse in patients with colorectal cancer after surgery
In hepatocellular carcinoma, CheckMate 459 misses OS endpoint, but some interesting trends emerge
Heavily pre-treated GIST: ripretinib improves PFS
FGFR2+ cholangiocarcinoma: pemigatinib active as second-line treatment
IDH1+ cholangiocarcinoma: phase 3 results show improved PFS
Advanced colorectal cancer and BRAF mutations: triplet combination improves survival
Genitourinary Cancers
25% reduction in the risk of death in patients with nmCRPC treated with apalutamide
Enfortumab vedotin and pembrolizumab in advanced bladder cancer: initial results
PARP inhibition in selected patients slows progression on advanced prostate cancer
PFS extension with immunotherapy + chemotherapy in urothelial cancer
Third-line in mCRPC: CARD trial
Prostate cancer: spare radiotherapy after surgery
Novel mode of action for kidney cancer treatment
Gynaecological Cancers
Ovarian cancer patients benefit from combined maintenance therapy
Combination of PARP inhibition plus chemotherapy in ovarian cancer
PFS benefit with niraparib as first-line maintenance in ovarian cancer
CNS Tumours
Ceritinib in ALK+ NSCLC brain metastases
Solid Tumours/Pan-Tumour Data
Mixed data: AMG 510 in tumours with KRASG12C
DNA profiling of carcinoma of unknown primary should inform treatment
Larotrectinib: safe and effective in TRK fusion-positive tumours
Related Articles
November 26, 2019
Preoperative chemotherapy for colon cancer
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy